Iovance Biotherapeutics, Inc. (2LB.F)
Chart Events
Performance Outlook
| Previous Close | 5.39 |
| Open | 5.23 |
| Bid | 5.54 x 100000 |
| Ask | 5.66 x 100000 |
| Day's Range | 5.23 - 5.23 |
| 52 Week Range | 5.23 - 16.66 |
| Volume | |
| Avg. Volume | 147 |
| Market Cap | 834.637M |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.56 |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.31 |
- GlobeNewswire
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
First TIL Therapy BLA Submission to U.S. Food and Drug AdministrationSAN CARLOS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced it has completed its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for lifileucel. Lifileucel is a tumor infiltrating lymphocyte (TIL) therapy intended as a treatment fo
- Insider Monkey
12 Best Biotech Stocks To Buy Under $20
In this piece, we will take a look at the 12 best biotechnology stocks to buy under $20. For more stocks, head on over to 5 Best Biotech Stocks To Buy Under $20. The biotechnology industry is one of the hottest sectors right now, particularly in the aftermath of the coronavirus pandemic since it was […]
- Simply Wall St.
Great week for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) institutional investors after losing 43% over the previous year
Key Insights Significantly high institutional ownership implies Iovance Biotherapeutics' stock price is sensitive to...
